middle.news
Imagion Biosystems Doubles Loss as It Files FDA IND for MagSense® HER2
3:14pm on Friday 27th of February, 2026 AEDT
•
Biotechnology
Read Story
Imagion Biosystems Doubles Loss as It Files FDA IND for MagSense® HER2
3:14pm on Friday 27th of February, 2026 AEDT
Key Points
Net loss doubled to $4.31 million in 2025
Raised $3.5 million in equity capital to fund clinical development
Filed FDA IND application for MagSense® HER2 molecular MRI imaging agent
Strengthened board and US management with key appointments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMAGION BIOSYSTEMS (ASX:IBX)
OPEN ARTICLE